Tonix Pharmaceuticals Holding Corp (TNXP)
0.7338
0.00 (0.00%)
USD |
NASDAQ |
Jul 02, 16:00
0.7445
+0.01
(+1.46%)
After-Hours: 20:00
Tonix Pharmaceuticals Research and Development Expense (Annual): 86.66M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 86.66M |
| December 31, 2022 | 81.88M |
| December 31, 2021 | 68.84M |
| December 31, 2020 | 36.16M |
| December 31, 2019 | 18.19M |
| December 31, 2018 | 17.56M |
| December 31, 2017 | 13.34M |
| Date | Value |
|---|---|
| December 31, 2016 | 28.53M |
| December 31, 2015 | 35.50M |
| December 31, 2014 | 18.62M |
| December 31, 2013 | 4.65M |
| December 31, 2012 | 2.584M |
| December 31, 2011 | 1.158M |
| December 31, 2010 | 0.5843M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
18.19M
Minimum
2019
86.66M
Maximum
2023
58.34M
Average
68.84M
Median
2021
Research and Development Expense (Annual) Benchmarks
| ThermoGenesis Holdings Inc | 1.284M |
| Assure Holdings Corp | -- |
| Vigil Neuroscience Inc | 60.93M |
| Allakos Inc | 150.91M |
| RAPT Therapeutics Inc | 101.00M |